

# RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

# Enantiopure synthesis of 7-(1-pyrindanyl)propargyl ethers as rasagiline analogues *via* chemical or enzymatic resolution of 1-pyrindan-7-ol

Carlos A. D. Sousa,<sup>a\*</sup> Ivo E. Sampaio-Dias,<sup>b</sup> Fabio Rizzo-Aguiar,<sup>b</sup> Xerardo Garcia-Mera,<sup>c</sup> José E. Rodríguez-Borges<sup>b</sup>

<sup>a</sup> REQUIMTE/LAQV, Departamento de Química e Bioquímica da Universidade do Porto, Rua do Campo Alegre, 4169-007 Porto, Portugal

<sup>b</sup> REQUIMTE/UCIBIO, Departamento de Química e Bioquímica da Universidade do Porto, Rua do Campo Alegre, 4169-007 Porto, Portugal

<sup>c</sup> Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain

[carlos.sousa@fc.up.pt](mailto:carlos.sousa@fc.up.pt)

## Abstract

In this work, the enantiopure synthesis of 7-(1-pyrindanyl)propargyl ethers – rasagiline analogues - *via* chemical and/or enzymatic resolution of the racemic precursor 1-pyrindan-7-ol is described. (*R*)-methoxyphenylacetic acid - (*R*)-MPAA - and (*S*)-methoxyphenylacetic acid - (*S*)-MPAA were used as chemical resolution agents, whereas *Candida antarctica* lipase B (CALB) was employed as kinetic resolution catalyst. The enzymatic resolution was successfully achieved by two different

approaches: 1) transesterification of racemic 1-pyrindan-7-ol, which was found to selectively acylate the (*R*)-enantiomer with high efficiency; 2) hydrolysis of the racemic 7-(1-pyrindanyl)acetate, which was also highly selective to the (*R*)-enantiomer. The enzymatic hydrolysis was performed in a non-aqueous solvent using a lipase with significant absorbed water content. The configuration of the two enantiomers of 1-pyrindan-7-ol (and consequently of the 7-(1-pyrindanyl)propargyl ethers) were unequivocally determined by X-ray crystallography and/or specific optical rotation.

### Keywords


Rasagiline analogues; pyrindane; chiral resolution; enzymatic transesterification; enzymatic hydrolysis;

### 1. Introduction

Neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, are incurable, resulting in progressive degeneration and/or death of neuron cells. Neurodegenerative diseases are an important cause of death among aged population worldwide. Even though several progresses have been made in the last decade, the current therapies do not fully correspond to the expectations of patients and physicians. Therefore, the discovery of new neuroprotective agents that improve the potential of the existing therapeutic drugs or the introduction of new alternative therapies are mandatory and urgent challenges.

Rasagiline (**1**, fig 1) is a potent, selective and irreversible inhibitor of monoamine oxidase type B (MAO-B) used as a monotherapy in early Parkinson's disease.<sup>1</sup> The

propargyl group is strongly related with the neuroprotective activity due to its ability to bind covalently to MAO-B and inhibit it.<sup>2</sup> In addition, the configuration of the chiral centre of rasagiline (*R*-enantiomer) is vital for its action as inhibitor of MAO-B. On the other hand, the *S*-enantiomer of rasagiline show cyto- and cardio-protective effects.<sup>3</sup> Recent studies also reveal that rasagiline salts decrease human melanoma tumor growth *in vivo*.<sup>4</sup>



**Figure 1.** (*R*)-Rasagiline (**1**) and a rasagiline analogue, 7-(1-pyrindanyl) propargyl ether (**2**).

Concerning the neuroprotective properties of rasagiline, many efforts have focused on exploiting rasagiline derivatives.<sup>1-2,5</sup> Our research group has been working in the synthesis of a new class of rasagiline analogs, derived from 1-pyrindane (6,7-dihydro-5*H*-cyclopenta[*b*]pyridine).<sup>6</sup> When compared with indane, the 1-pyrindane moiety may increase the affinity of the drug to the MAO-B enzyme due to the presence of the nitrogen atom in the aromatic ring. There are pyrindane derivatives which act as receptor antagonists of endothelin.<sup>7</sup> In this context, some pyrindane derivatives are being evaluated as therapeutic agents for the treatment of hypertension, congestive heart failure and kidney diseases.<sup>8</sup> More research involving pyrindanes reveal a scope of derivatives with potential for application as cardiogenic agents, bactericides and antifungals,<sup>9,10</sup> and inhibitors of phosphatase.<sup>11</sup>


In a previous work, we described the synthesis of racemic 7-(1-pyrindanyl) propargyl ether (**2**) as a rasagiline analogue.<sup>6</sup> Considering the influence of the configuration of the

chiral centre of rasagiline in its biological activity, an expeditious methodology for the enantiopure synthesis of **2** is mandatory. Thus, in this work we describe the enantiopure synthesis of **2** via chemical or enzymatic resolution of the racemic precursor 1-pyrindan-7-ol.

The resolution of racemic 1-pyrindan-7-ol (**3**) may also find application in the area of asymmetric catalysis due to its interesting structure. The simultaneous presence of the pyrindanic nitrogen atom and the hydroxyl group bonded to an enantiopure chiral centre prefigure molecule **3** as a good ligand for metal complexation. In fact, 1-pyrindane derivatives have been studied as asymmetric catalysts.<sup>12</sup>

## 2. Results and discussion

The optimized synthesis of racemic 1-pyrindan-7-ol **3** was previously reported by our research group.<sup>6</sup> By this method, 2,3-cyclopentenopyridine (**4**) is oxidized with *m*-chloroperbenzoic acid to its respective *N*-oxide (**5**) in high yields, which is subsequently treated with acetic anhydride to afford compound **6** through Boekelheide rearrangement.<sup>13</sup> Hydrolysis of **6** with potassium hydroxide in ethanol yields alcohol **3** (scheme 1).




**Scheme 1.** Optimized synthesis of alcohol **3**.<sup>6</sup> Reagents and conditions: (i) *m*-CPBA,  $\text{CH}_2\text{Cl}_2$ , r. t., 2 h, 99%; (ii)  $\text{Ac}_2\text{O}$ ,  $100^\circ\text{C}$ , 2h, 72%; (iii)  $\text{KOH}$ ,  $\text{EtOH}$ , r. t., 1 h, 90%.

From compound **3**, a wide range of derivatives may be prepared, including 7-(1-pyrindanyl) propargyl ether. Thus, it is of crucial importance to achieve the pure enantiomers of **3** as precursors for such derivatives. In order to resolve racemate **3**, two approaches were tested: a) chemical resolution and b) enzymatic resolution.

### 2.1. Chemical resolution

The protocol for chemical resolution of **3** comprised its esterification with (*R*)-methoxyphenylacetic acid - (*R*)-MPAA - and (*S*)-methoxyphenylacetic acid - (*S*)-MPAA – followed by posterior chromatographic separation of the resultant diastereoisomers **7** and **8**, respectively (scheme 2). Two esterification protocols were tested: a) Mitsunobu reaction<sup>14</sup> and b) Steglich esterification.<sup>15</sup> In the Mitsunobu reaction, racemic **3** was reacted with (*R*)-MPAA in the presence of triphenylphosphine and DEAD during 20 h. Two new compounds were formed and all the starting material was consumed (TLC). After chromatographic separation, the two diastereoisomers **7a** and **7b** were obtained in 30 % and 31 % yields, respectively. It is noteworthy that the chromatographic separation was hampered by the presence of triphenylphosphine oxide in the reaction crude.




**Scheme 2.** Procedure for chemical resolution of  $(\pm)\text{-3}$  using  $(R)\text{-MPAA}$  and  $(S)\text{-MPAA}$  as resolution agents.

In the Steglich esterification, racemic **3** was reacted with  $(R)\text{-MPAA}$  in the presence of DCC and catalytic amounts of DMAP during 4 hours. After separation by chromatographic column, the two diastereoisomers **7a** and **7b** were obtained in 32 % and 38 % yields, respectively. Taking into account both the reaction yields and the simplicity of the process, the Steglich esterification was preferred over the Mitsunobu

reaction to proceed with the esterification of ( $\pm$ )-**3** with (*S*)-MPAA, to afford the diastereoisomers **8a** and **8b**. The specific optical rotation of **7a/b** and **8a/b** were determined and their values are showed in scheme 2.  $^1\text{H-NMR}$  spectrum of **7a** was found identical to **8a**, proving they are enantiomers; in the same way, **7b** was confirmed as enantiomer of **8b**.

Treatment of each pair of diastereoisomers with KOH then afforded the corresponding enantiopure aminoalcohols **3** in good yields ( $\approx 90\%$ ). The specific optical rotation of the four samples were consistent ( $[\alpha]_{\text{D}} = +65$  for **3** resulting from hydrolysis of **7a/8b** and  $-65$  for **3** resulting from **7b/8a**). Chiral HPLC analysis confirmed enantiomeric purity higher than 99.3%.

As the diastereoisomers **7/8** were oils, the enantiopure ( $-$ )-**3** was condensed with the amino acid (*S*)-Boc-L-Leu-OH to afford the respective ester **9**, which was obtained as a white solid. After crystallization it was analyzed by X-ray crystallography and revealed to have (*S,S*) configuration (figure 2).<sup>16</sup> By crossing all this information ( $^1\text{H-NMR}$ ,  $[\alpha]_{\text{D}}$  and X-ray analysis), we unequivocally determined the complete configuration of each stereoisomer as are represented in scheme 2.




**Figure 2.** X-ray crystallographic structure of compound **9**.



Amino acid (*S*)-Boc-L-Leu-OH was also tested as resolution agent of ( $\pm$ )-**3**, but the resemblance on the  $R_f$  of the corresponding diastereoisomers makes it unsuitable for chromatographic separation.

## 2.2. Enzymatic resolution

The enzymatic resolution of ( $\pm$ )-**3** was tested by using Novozym<sup>®</sup> 435 - *Candida antarctica* lipase B (CALB) - a serine hydrolase immobilized on an hydrophobic carrier (acrylic resin). Lipases are a class of enzymes that catalyze the breakdown of lipids by hydrolysis of ester bonds; however, in organic media the lipases can also be used to catalyze esterification and transesterification reactions.<sup>17</sup> In fact, a survey through the literature shows the esterification and transesterification as the most used lipase-catalyzed reactions for the resolution of the two enantiomers of a racemic alcohol. We herein tested two methods for the kinetic enzymatic resolution of ( $\pm$ )-**3**: a) enzymatic transesterification, in which the racemic alcohol **3** was acylated using vinyl acetate as an irreversible acyl donor; b) hydrolysis of ester ( $\pm$ )-**6** (scheme 3).



**Scheme 3.** Protocols for the kinetic enzymatic resolution of ( $\pm$ )-**3**: enzymatic transesterification and hydrolysis of ( $\pm$ )-**6**.

The lipase-catalyzed transesterification and hydrolysis reactions were conducted under similar conditions (dry benzene, 18 h, room temperature, 50% w/w Novozym 435), with exception to the water content: transesterification was performed in the presence of molecular sieves and a hydrated lipase was employed in hydrolysis. The order of magnitude for the reaction enantioselectivities ( $E$ ) are presented in Table 1, which also lists  $[\alpha]_D$  values, enantiomeric excesses determined by chiral HPLC (Supplementary data) and substrate conversion rates ( $C$ ). It is worth mentioning that the calculation of enantiomeric excesses values (e.e.) through  $[\alpha]_D$  is consistent with those determined by HPLC.

**Table 1.** Enantioselectivities ( $E$ ),  $[\alpha]_D$ , enantiomeric excesses (e.e.) and substrate conversion rates ( $C$ ) for the lipase-catalyzed transesterification and hydrolysis reactions.

Reaction	Conversion <sup>a</sup> / %	Alcohol <b>3</b>		Acetate <b>6</b>		$E^b$
		e.e. / %	$[\alpha]_D$	e.e. / %	$[\alpha]_D$	
Transesterification	49	94	-61.9	>98	-17.1	>300
Hydrolysis	49	>98	+65.0	94	+16.2	>300

$$^a C = e.e._s / (e.e._s + e.e._p); ^b E = \ln[(1-c)(1-e.e._s)] : \ln[(1-c)(1+e.e._s)]^{18}$$

The enzymatic transesterification was found to selectively acylate the ( $R$ )-enantiomer of **3** with high efficiency, allowing subsequent chromatographic separation of the ( $S$ )-enantiomer ( $-$ )-**3** from ( $R$ )-7-(1-pyrindanyl)acetate ( $-$ )-**6**, which was then saponified to ( $R$ )-1-pyrindan-7-ol ( $+$ )-**3** (Scheme 3). On the other hand, hydrolysis of ( $\pm$ )-**6** was

highly selective to afford the (*R*)-enantiomer of **3**, which was then separated from the non-hydrolyzed (*S*)-7-(1-pyrindanyl)acetate (+)-**6** through chromatographic column. Subsequent saponification of (+)-**6** afforded (*S*)-1-pyrindan-7-ol (-)-**3**.

Under the mentioned conditions, the transesterification reaction allowed to obtain acetate (-)-**6** with e.e. > 98% and the remaining alcohol (-)-**3** with e.e. of 94%, giving an enantiomer ratio (*E*) higher than 300. In its turn, the hydrolysis of racemate (±)-**6** afforded (+)-**3** with e.e. > 98% and the remaining acetate (+)-**6** with e.e. of 94%, leading to similar *E*. In this way, virtual enantiopure (*R*)-1-pyrindan-7-ol [(+)-**3**] could be effectively prepared directly from (±)-**6** by substituting step *iii* represented in scheme 1 by the lipase-catalyzed hydrolysis protocol.


Obviously, the hydrolysis of esters is not possible in the absence of water. On the other hand, the use of aqueous media is not adequate to most of the organic reactions. Thus, since it is known that some amount of water may be fixed to proteins by hydrogen bonding as a water shell, we decided to use a CALB lipase with increased water content rather than adding water to the reaction mixture. As the enzymes are moisture absorbable, CALB was kept in the fridge during two days in a non-hermetic sealed vial prior to its use as catalyst in the hydrolysis reaction. In fact, there are previous observations suggesting that water absorbed to CALB takes part in the hydrolysis reaction.<sup>19</sup>

It is also worth mentioning that the selectivity observed for the *R* enantiomer is in agreement with Kazlauskas rule,<sup>20</sup> which states that most lipases resolve secondary alcohols to give the *R* enantiomers. This is related to the better positioning of the alcohol group in the stereospecific smaller pocket of the enzyme and the bulky group in the large cavity. The excellent selectivity of CALB for the *R* enantiomer of **6** was demonstrated for the enzymatic hydrolysis: two filtered and dried samples of the reaction mixture after 18

h and 48 h were analyzed by  $^1\text{H-NMR}$ , which showed similar proportions of alcohol **3**/acetate **6**. This shows that CALB did not hydrolyze the *S* enantiomer of **6**.

### 2.3. Synthesis of enantiopure 7-(1-pyrindanyl) propargyl ethers (**2**)

The enantiopure propargyl ethers (+)-**2** and (-)-**2** were easily prepared with good yield by bimolecular nucleophilic substitution reaction with propargyl bromide from the respective enantiopure alcohols (+)-**3** and (-)-**3**, respectively (scheme 4).



**Scheme 4.** Formation of 7-(1-pyrindanyl)propargyl ethers (-)-**2** and (+)-**2** from the respective enantiopure alcohols (+)-**3** and (-)-**3**, respectively.

### 3. Conclusion

The preparation of combinatorial libraries for the search for new drugs helps both in the identification of prototype compounds as in the optimization of these. Hence, the preparation of a wide range of rasagiline analogs derived from 1-pyrindane is an important route to explore for the identification of bioactive molecules, in particular with neuroprotective properties. However, it is known that the configuration of the chiral centre of rasagiline (*R*-enantiomer) is vital for its action as inhibitor of MAO-B. With this in mind, enantiopure (*R*)- and (*S*)-7-(1-pyrindanyl)propargyl ethers were prepared as rasagiline analogues, by using chemical or enzymatic resolution of their

precursor, the previously described 1-pyrindan-7-ol.<sup>6</sup> The chemical resolution, in which (*R*)- and (*S*)-methoxyphenylacetic acids were used as resolution agents, was found to be more laborious, time consuming and expensive. However, excellent results were obtained, the alcohols (+)-**3** and (-)-**3** being obtained with fair overall yields and virtually complete enantiopurity (the enantiomeric purity of chemically resolved enantiomers depends on the enantiopurity of the used resolution agent). On the other hand, enzymatic resolution using CALB revealed to be easy, cheaper and simple to perform. However, only the (*R*)-enantiomer was obtained with high enantiomeric purity. This means that, despite the excellent enantioselectivity of the process, the (*S*)-enantiomer needs to be further purified by some other method for absolute enantiomeric purity. This applies to both the lipase-catalyzed transesterification of (±)-**3** and to the hydrolysis of (±)-**6**. The preparation of enantiopure (+)-**3** and enantioenriched (-)-**3** directly from (±)-**6** is also an advantage since no additional steps are introduced in the synthetic procedure. Furthermore, the use of hydrated CALB significantly simplified the process because it avoids the need of water addition in the reaction media, the use of aqueous solvents and the need of pH control. Thus, the lipase-catalyzed hydrolysis reaction revealed to be the better option for this resolution process.

We believe this strategy will also find important application in asymmetric catalysis, since it allows a straightforward preparation of the two isolated enantiomers of 1-pyrindan-7-ol derivatives as interesting chiral ligands.

#### 4. Experimental

All chemicals were of reagent grade and were obtained from Sigma-Aldrich or Bachem and used without further purification. CALB (Novozym<sup>®</sup> 435), was from Novo Nordisk. Flash chromatography was performed on silica gel (Merck 60, 230-240 mesh),

and analytical TLC was carried out on pre-coated silica gel plates (Merck 60 F<sub>254</sub>, 0.25 mm) using UV light and/or an ethanolic solution of phosphomolybdic acid (followed by gentle heating) for visualization. Melting points were determined on an electrothermal melting point apparatus and are uncorrected. <sup>1</sup>H- and <sup>13</sup>C-NMR spectra were recorded in a Bruker Avance III 400 at Centro de Materiais da Universidade do Porto - CEMUP. The NMR spectra were calibrated using TMS as internal standard. Mass spectra were recorded on a LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) controlled by *LTQ Tune Plus 2.5.5* and *Xcalibur 2.1.0* (CEMUP). Optical rotations were measured on a thermostated *Jasco P-2000* digital polarimeter using a sodium lamp.

Chiral HPLC analyses were performed on a Thermo Scientific UHPLC Dionex UltiMate 3000 BioRS, using a CHIRALCEL<sup>®</sup> OD-H column.

#### 4.1. Chemical resolution of (±)-**3**

4.1.1. Esterification of (±)-**3** with (*R*)-MPAA through Mitsunobu reaction: In a round bottom flask, coupled with a dropping funnel and under argon atmosphere, a solution of (±)-**3** (0.310 g, 2.29 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (10 ml) was prepared and kept into an ice bath. Triphenylphosphine (0.89 g, 3.4 mmol) and (*R*)-MPAA (0.56 g, 3.4 mmol) were added and then 3.0 ml of a solution of DEAD in THF (40%, 6.8 mmol) was added dropwise from the dropping funnel. The mixture was left to react during 16 h under stirring. Water was added and the phases were separated. The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 20 ml), the organic layers were washed with water (20 ml) and saturated aqueous solution of sodium chloride (20 ml), combined and dried over anhydrous sodium sulfate. After removal of solvents, the obtained crude was purified by chromatographic column (eluent: Hex/AcOEt 1:4). The two fractions corresponding to

the two diastereoisomers **7a/7b** were collected as white solids with yields of 30 % and 31 %, respectively.

*4.1.2. Esterification of (±)-3 with (R)-MPAA and (S)-MPAA through Steglich protocol:* In a round bottom flask, under argon atmosphere, a solution of (±)-**3** (0.720 g, 5.33 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (20 ml) was prepared and then DCC (1.32 g, 6.39 mmol), (R)- or (S)-MPAA (0.890 g, 5.33 mmol) and a catalytic amount of DMAP (5.0 mg) were added. The system was left to react at room temperature during 4 h. After the disappearance of the starting material (TLC) 50 ml of saturated sodium bicarbonate was added. The phases were separated and the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 50 ml). The organic layers were then washed with water (50 ml) and saturated aqueous solution of sodium chloride (50 ml), combined and dried over anhydrous sodium sulfate. After removal of solvents, the obtained crude was purified by chromatographic column (eluent: Hex/AcOEt 1:4). The two fractions corresponding to the two diastereoisomers **7a/7b** were collected as white solids with yields of 32 % and 38 %, respectively; **8a/8b** were also obtained as white solids with yields of 32 % and 36 %, respectively.

*(R)-(R)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl 2-phenylpropanoate (7a) <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz), δ (ppm):* 2.08 (1H, dddd, *J* = 14.2, 9.1, 5.2, 4.2 Hz, H<sub>6<sub>anti</sub></sub>), 2.58 (1H, dddd, *J* = 14.3, 8.7 Hz, 7.4, 5.6 Hz, H<sub>6<sub>syn</sub></sub>), 2.88 (1H, ddd, *J* = 16.4, 8.7, 5.2 Hz, H<sub>5<sub>anti</sub></sub>), 3.02-3.14 (1H, m, H<sub>5<sub>syn</sub></sub>), 3.42 (3H, s, OCH<sub>3</sub>), 4.83 (1H, s, OC(O)CH), 6.21 (1H, dd, *J* = 7.5, 4.2 Hz, H7), 7.11-7.24 (1H, m, H3), 7.29-7.37 (3H, m, 2 × H'<sub>meta</sub> and H'<sub>para</sub>), 7.43-7.49 (2H, m, 2 × H'<sub>ortho</sub>), 7.58 (1H, d, *J* = 8.0 Hz, H4), 8.46 (1H, s, H2); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 100 MHz), δ (ppm): 27.8 (C5), 30.3 (C6), 57.5 (OCH<sub>3</sub>), 78.0 (C7), 82.8 (OC(O)CH), 123.4 (C3), 127.2 (2 × C'<sub>meta</sub>), 128.5 (2 × C'<sub>ortho</sub>), 128.6 C'<sub>para</sub>), 133.1

(C4), 136.04 (C4a), 137.7 (C'<sub>ipso</sub>), 148.6 (C2), 159.8 (C7a), 170.5 (OC(O)CH); **ESI-HRMS**: calculated for [C<sub>17</sub>H<sub>17</sub>NO<sub>3</sub> + H]<sup>+</sup> 284.1281, obtained 284.1282; [α]<sub>D</sub><sup>20</sup> = -34.9 (c1, CHCl<sub>3</sub>); **m. p.** = 219-224 °C;

*(R)-(S)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl 2-phenylpropanoate (7b)* **<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz), δ (ppm)**: 1.73 (1H, dddd, *J* = 14.3, 8.6, 5.7, 4.6 Hz, H6<sub>anti</sub>), 2.50 (1H, dddd, *J* = 14.0, 8.4 Hz, 7.4, 5.6 Hz, H6<sub>syn</sub>), 2.84 (2H, m, H5), 3.45 (3H, s, OCH<sub>3</sub>), 4.86 (1H, s, OC(O)CH), 6.21 (1H, dd, *J* = 7.4, 4.6 Hz, H7), 7.21 (1H, dd, *J* = 7.7, 4.8 Hz, H3), 7.28-7.37 (3H, m, 2 × H'<sub>meta</sub> and H'<sub>para</sub>), 7.38-7.47 (2H, m, 2 × H'<sub>ortho</sub>), 7.58 (1H, d, *J* = 8.0 Hz, H4), 8.51 (1H, s, H2); **<sup>13</sup>C-NMR (CDCl<sub>3</sub>, 100 MHz), δ (ppm)**: 27.8 (C5), 30.4 (C6), 57.5 (OCH<sub>3</sub>), 77.7 (C7), 82.1 (OC(O)CH), 123.6 (C3), 127.3 (2 × C'<sub>meta</sub>), 128.5 (2 × C'<sub>ortho</sub>), 128.6 C'<sub>para</sub>), 133.6 (C4), 136.3 (C4a), 138.0 (C'<sub>ipso</sub>), 148.4 (C2), 159.6 (C7a), 170.4 (OC(O)CH); **ESI-HRMS**: calculated for [C<sub>17</sub>H<sub>17</sub>NO<sub>3</sub> + H]<sup>+</sup> 284.1281, obtained 284.1284; [α]<sub>D</sub><sup>20</sup> = +23.2 (c1, CHCl<sub>3</sub>); **m. p.** = 219-221 °C;

*(S)-(S)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl 2-phenylpropanoate (8a)* **<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz), δ (ppm)**: 2.08 (1H, dddd, *J* = 14.2, 8.8, 5.2, 4.3 Hz, H6<sub>anti</sub>), 2.58 (1H, dddd, *J* = 14.3, 8.8 Hz, 7.5, 5.6 Hz, H6<sub>syn</sub>), 2.88 (1H, ddd, *J* = 16.3, 8.8, 5.2 Hz, H5<sub>anti</sub>), 3.03-3.14 (1H, m, H5<sub>syn</sub>), 3.43 (3H, s, OCH<sub>3</sub>), 4.84 (1H, s, OC(O)CH), 6.22 (1H, dd, *J* = 7.5, 4.3 Hz, H7), 7.18 (1H, dd, *J* = 7.7, 4.8 Hz, H3), 7.28-7.39 (3H, m, 2 × H'<sub>meta</sub> and H'<sub>para</sub>), 7.42-7.49 (2H, m, 2 × H'<sub>ortho</sub>), 7.59 (1H, d, *J* = 8.0 Hz, H4), 8.45 (1H, s, H2); **<sup>13</sup>C-NMR (CDCl<sub>3</sub>, 100 MHz), δ (ppm)**: 27.9 (C5), 30.4 (C6), 57.6 (OCH<sub>3</sub>), 78.0(C7), 82.9 (OC(O)CH), 123.5 (C3), 127.2 (2 × C'<sub>meta</sub>), 128.5 (2 × C'<sub>ortho</sub>), 128.6 C'<sub>para</sub>), 133.2 (C4), 136.2 (C4a), 137.8 (C'<sub>ipso</sub>), 148.6 (C2), 159.9 (C7a), 170.6 (OC(O)CH); **ESI-HRMS**: calculated for [C<sub>17</sub>H<sub>17</sub>NO<sub>3</sub> + H]<sup>+</sup> 284.1281, obtained 284.1280; [α]<sub>D</sub><sup>20</sup> = +35.1 (c1, CHCl<sub>3</sub>); **m. p.** = 220-224 °C;



(*S*)-(*R*)-6,7-dihydro-5*H*-cyclopenta[*b*]pyridin-7-yl 2-phenylpropanoate (**8b**) <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz), δ (ppm): 1.73 (1H, dddd, *J* = 14.2, 8.6, 5.7, 4.5 Hz, H6<sub>anti</sub>), 2.50 (1H, dddd, *J* = 14.1, 8.4 Hz, 7.3, 5.6 Hz, H6<sub>syn</sub>), 2.75-2.93 (2H, H5), 3.45 (3H, s, OCH<sub>3</sub>), 4.86 (1H, s, OC(O)CH), 6.21 (1H, dd, *J* = 7.4, 4.6 Hz, H7), 7.20 (1H, dd, *J* = 7.7, 4.8 Hz, H3), 7.29-7.36 (3H, m, 2 × H'<sub>meta</sub> and H'<sub>para</sub>), 7.39-7.46 (2H, m, 2 × H'<sub>ortho</sub>), 7.57 (1H, d, *J* = 7.8 Hz, H4), 8.51 (1H, d, *J* = 5.0 Hz, H2); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 100 MHz), δ (ppm): 27.7 (C5), 30.3 (C6), 57.5 (OCH<sub>3</sub>), 77.7 (C7), 82.1 (OC(O)CH), 123.5 (C3), 127.3 (2 × C'<sub>meta</sub>), 128.5 (2 × C'<sub>ortho</sub>), 128.6 C'<sub>para</sub>, 133.3 (C4), 136.3 (C4a), 137.8 (C'<sub>ipso</sub>), 148.6 (C2), 159.8 (C7a), 170.4 (OC(O)CH); ESI-HRMS: calculated for [C<sub>17</sub>H<sub>17</sub>NO<sub>3</sub> + H]<sup>+</sup> 284.1281, obtained 284.1285; [α]<sub>D</sub><sup>20</sup> = -23.4 (c1, CHCl<sub>3</sub>); m. p. = 219-223 °C;

#### 4.1.3. Hydrolysis of the diastereoisomers **7a/7b** and **8a/8b**:

In a round bottom flask, a solution of diastereomeric pure **7a/7b** or **8a/8b** (0.400 g, 1.41 mmol) in ethanol (10 ml) was prepared and then 0.16 g (2.8 mmol) of KOH was added. The mixture was stirred for 2 h at room temp. After the disappearance of the starting material (TLC) the solvent was evaporated under reduced pressure, CH<sub>2</sub>Cl<sub>2</sub> (50 ml) and a saturated aqueous solution of ammonium chloride (50 ml) were added and the phases separated. The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 50 ml). The organic layers were then washed with water (50 ml) and saturated sodium chloride (50 ml), combined and dried over anhydrous sodium sulfate. After removal of solvents, the obtained crude was purified by chromatographic column (eluent: AcOEt) and a white solid was obtained with yields between 87-90%. The NMR spectra of (±)-**3**, (+)-**3** and (-)-**3** were found identical.

**<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz), δ(ppm):** 2.05-2.14 (1H, m, H<sub>6<sub>anti</sub></sub>), 2.52-2.61 (1H, m, H<sub>6<sub>syn</sub></sub>), 2.80-2.88 (1H, m, H<sub>5<sub>anti</sub></sub>), 3.07 (1H, ddd, *J* = 4.3, 8.9, 13.2 Hz, H<sub>5<sub>syn</sub></sub>), 4.76 (1H, bs, OH), 5.28 (1H, t, *J* = 6.0 Hz, H<sub>7</sub>), 7.16 (1H, dd, *J* = 5.0, 7.6 Hz, H<sub>3</sub>), 7.59 (1H, dd, *J* = 0.6, 7.6 Hz, H<sub>4</sub>), 8.43 (1H, d, *J* = 4.9 Hz, H<sub>2</sub>). **<sup>13</sup>C-NMR (CDCl<sub>3</sub>, 100 MHz), δ (ppm):** 28.4 (C<sub>5</sub>), 33.6 (C<sub>6</sub>), 74.8 (C<sub>7</sub>), 123.6 (C<sub>3</sub>), 134.4 (C<sub>4</sub>), 137.5 (C<sub>4a</sub>), 148.4 (C<sub>2</sub>), 166.0 (C<sub>7a</sub>); **m. p. (±)-**3**** = 80-83 °C; **m. p. (+)-**3**** = 60-61 °C; **m. p. (-)-**3**** = 59-61 °C.  $[\alpha]_D^{20}$  (+)-**3** = +65 (*c*<sub>1</sub>, CHCl<sub>3</sub>);  $[\alpha]_D^{20}$  (-)-**3** = -65 (*c*<sub>1</sub>, CHCl<sub>3</sub>).

*4.1.4. Synthesis of (S)-(S)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl 2-((tert-butoxycarbonyl)amino)-4-methylpentanoate (9):*

In a round bottom flask, Boc-L-Leu-OH (0.317 g, 1.27 mmol) was diluted in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (20 ml) under argon atmosphere and then DIPEA (0.42 ml, 2.54 mmol) was added and the mixture was allowed to stir for 15 min. After that, TBTU (0.408 g, 1.27 mmol) was added and stirred for an additional 30 min followed by addition of alcohol (-)-**3** (0.172 g, 1.27 mmol) and a catalytic amount of DMAP. The mixture was left under stirring at room temperature overnight. The solvent was removed in a rotary evaporator, the crude was diluted with AcOEt (50 ml) and then water (50 ml) was added. The phases were separated and the organic layer was washed with aqueous saturated solution of NaHCO<sub>3</sub> (3 × 50 ml) and brine (50 ml). The organic phase was then dried with anhydrous sodium sulfate, filtered and the solvent was removed to dryness. The resulting residue was purified by chromatography on silica gel (eluent: Et<sub>2</sub>O/Hex 3:1) obtaining **9** as a white solid (0.278 g, 63 %).

**<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz), δ (ppm):** 0.92 (d, *J* = 6.5 Hz, 6H, H<sub>L-5</sub>), 1.44 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), 1.55 – 1.64 (m, 1H, H<sub>L-4</sub>), 1.66 – 1.82 (m, 2H, H<sub>L-3</sub>), 2.20 – 2.31 (m, 1H, H<sub>6<sub>anti</sub></sub>), 2.65 – 2.77 (m, 1H, H<sub>6<sub>syn</sub></sub>), 2.95 – 3.05 (m, 1H, H<sub>5<sub>anti</sub></sub>), 3.14 – 3.26 (m, 1H,

H5<sub>syn</sub>), 4.30 (td,  $J = 9.1, 4.2$  Hz, 1H, H<sub>L-2</sub>), 5.11 (d,  $J = 8.2$  Hz, 1H, H7), 6.32 (dd,  $J = 7.0, 4.7$  Hz, 1H, H3), 7.39 – 7.54 (m, 1H, H4), 7.89 (d,  $J = 7.0$  Hz, 1H, CONH), 8.57 (d,  $J = 5.0$  Hz, 1H, H2); <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 100 MHz),  $\delta$  (ppm): 21.9 (C<sub>L-5</sub>), 23.0 (C<sub>L-5</sub>), 24.9 (C<sub>L-4</sub>), 28.1 (C6), 28.4 (C(CH<sub>3</sub>)<sub>3</sub>), 30.6 (C5), 41.7 (C<sub>L-3</sub>), 52.4 (C<sub>L-2</sub>), 77.6 (C7), 79.8 (C(CH<sub>3</sub>)<sub>3</sub>), 123.9 (CH), 134.1 (CH), 138.5 (C4a), 148.0 (C2), 155.6 (C), 159.7 (C), 173.3 (CO<sub>2</sub>CH<sub>3</sub>); **ESI-HRMS**: calculated for [C<sub>19</sub>H<sub>29</sub>N<sub>2</sub>O<sub>4</sub> + H]<sup>+</sup> 349.21218, obtained 349.21211;  $[\alpha]_{\text{D}}^{25} = -7.5$  (c1, CHCl<sub>3</sub>); **m. p.** = 75-78 °C.

## 4.2. Enzymatic resolution

### 4.2.1. Transesterification

In a round bottom flask, racemic alcohol ( $\pm$ )-**3** (0.500 g, 3.70 mmol) was diluted in anhydrous benzene (20 ml) under argon atmosphere and molecular sieves (0.200 g), and then Novozym<sup>®</sup> 435 (0.250 g, 50% w/w) was added followed by vinyl acetate (0.25 ml, 2.71 mmol). The mixture was stirred for 18 hours, at rt. The lipase was filtered off by simple filtration and the solvent of the filtrate was removed in a rotary evaporator. The resulting residue was purified by chromatography on silica gel (eluent: AcOEt). The early fractions afforded (*R*)-7-(1-pyrindanyl)acetate (-)-**6** as a yellow oil (49%, e.e. > 98%), and the later fractions the non-acetylated (*S*)-1-pyrindan-7-ol (-)-**3** (51%, e.e. 94%) as a white solid. The NMR spectra of (-)-**6** is identical to the corresponding racemic form previously reported.<sup>6</sup> (-)-**3**: **m.p.** = 59-61 °C,  $[\alpha]_{\text{D}}^{20} = -61.9$  (c1, CHCl<sub>3</sub>); (-)-**6**:  $[\alpha]_{\text{D}}^{20} = -17.1$  (c1, CHCl<sub>3</sub>).

### 4.2.2. Hydrolysis of ( $\pm$ )-7-(1-pyrindanyl)acetate ( $\pm$ )-**6**

In a round bottom flask, racemic ester ( $\pm$ )-**6** (0.500 g, 2.82 mmol) was diluted in benzene (20 ml) and then hydrated Novozym<sup>®</sup> 435 (0.250 g, 50% w/w) was added

(Novozym<sup>®</sup> 435 was previously kept in the fridge during two days in a non-hermetic sealed vial prior to its use). The mixture was stirred for 18 hours, at rt. After the same work-up protocol used for transesterification reaction, the resulting residue was purified by chromatography on silica gel (eluent: AcOEt). The early fractions afforded the non-hydrolyzed (*S*)-7-(1-pyrindanyl)acetate (+)-**6** as a yellow oil (51%, 94% e.e.) and the later fractions (*R*)-1-pyrindan-7-ol (+)-**3** as a white solid (49%, e.e. > 98%). The NMR spectra of (+)-**3** is identical to the corresponding racemic form previously reported.<sup>6</sup> (+)-**3**: m.p. = 60-61 °C,  $[\alpha]_D^{20} = +65.0$  (*c*1, CHCl<sub>3</sub>); (+)-**6**:  $[\alpha]_D^{20} = +16.2$  (*c*1, CHCl<sub>3</sub>). <sup>1</sup>H-NMR spectra of two filtered and dried samples of the reaction mixture after 18h and 48h are presented in figure 14 of electronic supplementary information.

*4.3. Procedure for the synthesis of (R)- or (S)-2*: In a round bottom flask, under argon atmosphere, a solution of enantiomeric pure (*R*)- or (*S*)-**3** (0.300 g, 2.22 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was prepared. 0.50 ml (6.6 mmol) of propargyl bromide and potassium *tert*-butoxide (0.410 g, 3.33 mmol) were added and the system was let under stirring and inert atmosphere during 20 h. 50 ml of saturated sodium bicarbonate were added, the phases were separated and the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 ml). The organic layers were washed with water (50 ml) and saturated sodium chloride (50 ml), combined and dried over anhydrous sodium sulfate. After removal of solvents, the obtained crude was purified by chromatographic column (eluent: AcOEt). The fractions corresponding to (*R*)- or (*S*)-**2** were collected, affording oils after evaporation of the solvent, with yields of 73 % and 71 %, respectively. The NMR spectra of (±)-**2**,<sup>6</sup> (*R*)-**2** and (*S*)-**2** were found identical.

*(R)- or (S)-7-(prop-2-ynoxy)-6,7-di-hydro-5H-cyclopenta[b]pyridine ((R)- or (S)-2):*  
**<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 400 MHz), δ(ppm):** 2.09-2.16 (1H, m, H6<sub>anti</sub>), 2.32-2.39 (1H, m, H6<sub>syn</sub>), 2.42 (1H, t, *J* = 2.4 Hz, OCH<sub>2</sub>CCH), 2.77 (1H, ddd, *J* = 13.3, 8.7, 4.6 Hz, H5<sub>anti</sub>), 3.00-3.08 (1H, m, H5<sub>syn</sub>), 4.38 (1H, dd, *J* = 15.6, 2.4 Hz, OCH<sub>a</sub>H<sub>b</sub>CCH), 4.46 (1H, dd, *J* = 15.7, 2.4 Hz, OCH<sub>a</sub>H<sub>b</sub>CCH) 4.98 (1H, dd, *J* = 7.0, 3.7, H7), 7.10 (1H, dd, *J* = 7.6, 4.9 Hz, H3), 7.51 (1H, dd, *J* = 7.6, 0.6 Hz, H4), 8.39 (1H, d, *J* = 4.9 Hz, H2); **<sup>13</sup>C-NMR (CDCl<sub>3</sub>, 100 MHz), δ (ppm):** 28.8 (C5), 31.7 (C6), 57.4 (OCH<sub>2</sub>CCH), 75.1 (OCH<sub>2</sub>CCH), 81.1 (OCH<sub>2</sub>CCH), 81.8 (C7), 124.0 (C3), 1334.0 (C4), 138.2 (C4a), 148.9 (C2), 163.4 (C7a); **ESI-HRMS:** calculated for [C<sub>11</sub>H<sub>11</sub>NO + H]<sup>+</sup> 174.0919, obtained 174.0917; [α]<sub>D</sub><sup>20</sup> (*R*)-**2** = -38 (c1, CHCl<sub>3</sub>); [α]<sub>D</sub><sup>20</sup> (*S*)-**2** = +39 (c1, CHCl<sub>3</sub>);

5. *HPLC chiral analyses:* both racemates **3** and **6** were individually analyzed in order to determine the retention times of the respective enantiomers. A 0.5 ml/min flow of 90:10 hexane/isopropanol was used. It was verified that retention times of (±)-**3** and (±)-**6** were perfectly coincident. Thus, for an accurate evaluation, at the end of each enzymatic reaction alcohols **3** needed to be chromatographically separated from acetates **6** prior to HPLC analyses. Retention times: (*R*)-**3** = (*R*)-**6** = 15.9 min; (*S*)-**3** = (*S*)-**6** = 22.9 min.

### Acknowledgements

The work was funded by Fundação para a Ciência e a Tecnologia (FCT)/MEC and FEDER under Program PT2020 (project UID/QUI/50006/2013). CADS, IESD and FRA also thank FCT for the grants SFRH/BPD/80100/2011, SFRH/BD/93632/2013 and SFRH/BD/45545/2008, respectively. We also thank Novo Nordisk, Denmark, for the generous gifts of CALB lipase.

### Supplementary data

This material contains NMR spectra for compounds **2**, **3**, **6**, **7**, **8**, **9**, crystal data and structure refinement for **9** and Chiral HPLC chromatograms of compound **3** and **6**. Supplementary data associated with this article can be found, in the online version, at doi:

### References

1. a) M. B. H. Youdim; M. Fridkin; H. Zheng, *Mech. ageing Dev.*, 2005, **126**, 317-326; b) O. Rascol, D. J. Brooks, E. Melamed, W. Oertel, W. Poewe, F. Stocchi, E. Tolosa, *Lancet*, 2005, **365**, 947-954; c) D. R. Guay, *Am. J. Geriatr. Pharmacother.*, 2006, **4**, 330-46; d) V. Oldfield, G. M. Keating, C. M. Perry, *Drugs*, 2007, **67**, 1725–1747; e) D. A. Gallagher, A. Schrag, *CNS Drugs*, 2008, **22**, 563–586; f) O. Bar-Am, O. Weinreb, T. Amit, M. B. H. Youdim, *J Neurochem.*, 2010, **112**, 1131-1137; g) M. B. H. Youdim, *Exp. Neurobiol.*, 2013, **22**,1-10;
2. a) M. B. H. Youdim, M. Weinstock, *Mech. ageing Dev.*, 2002, **123**, 1081-1086; b) M. Naoi, W. Maruyama, M. B. H. Youdim, P. Yu, A. A. Boulton, *Inflammopharmacology*, 2003, **11**, 175-181; c) M. Yogev-Falach, T. Amit, O. Bar-Am, M. B. H. Youdim, *FASEB J*, 2003, **17**, 2325-2327; d) O. Bar-Am, O. Weinreb, T. Amit, M. B. H. Youdim, *FASEB J*, 2005, **19**, 1899-1904; e) C. Binda, F. Hubálek, M. Li, Y. Herzig, J. Sterling, D. E. Edmondson, A. Mattevi, *J. Med. Chem.*, 2005, **48**, 8148-8154;
3. Y. D. Barac, O. Bar-Am, E. Liani, T. Amit, L. Frolov, E. Ovcharenko, I. Angel, M. B. H. Youdim, O. Binah, *PLoS ONE*, 2012, **7**, e47890;

4. S. R. Meier-Davis, K. Dines, F. M. Arjmand, R. Hamlin, B. Huang, J. Wen, C. Christianson, J. Shudo, T. Nagata, *Cutan Ocul Toxicol.*, 2012, **31**, 312-317;
5. M. A. Siddiqui, G. Plosker, *Drugs & aging*, 2005, **22**, 83-91;
6. C.S. Pereira, S. Salgado, F. Rizzo-Aguiar, X. Garcia-Mera, J. E. Rodríguez-Borges, *Synlett*, 2013, **24**, 837-838;
7. Z. J. Song, M. Zhao, L. Frey, J. Li, L. Tan, C. Y. Chen, D. M. Tschaen, R. Tillyer, E. J. J. Grabowski, R. Volante, P. J. Reider, Y. Kato, S. Okada, T. Nemoto, H. Sato, A. Akao, T. Mase, *Org. Lett.*, 2001, **3**, 3357-3360;
8. Y. Kato, K. Niiyama, H. Jona, S. Okada, A. Akao, S. Hiraga, Y. Tsuchiya, K. Tomimoto, T. Mase, *Chem. Pharm. Bull.*, 2002, **50**, 1066-1072;
9. N. Robert, C. Verrier, C. Hoarau, S. Célanire, F. Marsais, *Arkivoc*, 2008, 92-100;
10. A. Altundas, S. Ayvaz, E. Logoglu, *Med. Chem. Res.*, 2011, **20**, 1-8;
11. S. Kolb, M. L. Goddard, A. Loukaci, O. Mondésert, B. Ducommun, E. Braud, C. Garbay, *Eur. J. Med. Chem.*, 2010, **45**, 896-901;
12. a) M. P. A. Lyle, A. A. Narine, P. D. Wilson, *J. Org. Chem.*, 2004, **69**, 5060-5064; b) M. P. A. Lyle, N. D. Draper, P. D. Wilson, *Org. Biomol. Chem.*, 2006, **4**, 877-885;
13. a) V. Boekelheide, W. J. Linn, *J. Am. Chem. Soc.*, 1954, **76**, 1286-1291; b) V. Boekelheide, W. L. Lehn, *J. Org. Chem.*, 1961, **26**, 428-430;
14. O. Mitsunobu, M. Eguchi, *Bull. Chem. Soc. Jpn.*, 1971, **44**, 3427-3430;
15. B. Neises, W. Steglich, *Angew. Chem. Int. Ed. Engl.*, 1978, **17**, 522-524;
16. The crystallographic data for the structure **9** have been deposited at the Cambridge Crystallographic Data Center as supplementary publication number CCDC 1404442.
17. P. Adlercreutz, *Chem. Soc. Rev.*, 2013, **42**, 6406-6436;

18. C.-S. Chen, C. J. Sih, *Angew. Chem. Int. Ed. Engl.*, 1989, **28**, 695-707;
19. M. Braner, S. Zielonka, J. Grzeschik, S. Krah, S. Lieb, D. Petras, X. Wagner, I. Ahmed, S. H. Huttenhain, *ChemCatChem*, 2012, **4**, 2050-2054;
20. R. J. Kazlauskas, A. N. E. Weissfloch, A. T. Rappaport, L. A. Cuccia, *J. Org. Chem.*, 1991, **56**, 2656–2665;



Enantiopure 7-(1-pyrindanyl)propargyl ethers – rasagiline analogues – were efficiently obtained *via* chemical and/or enzymatic resolution of the racemic precursor 1-pyrindan-7-ol

